Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 04, 2024 5:06pm
57 Views
Post# 35971406

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaApril 04, 2024 - The Biosecure Act prohibits federal contracting with “certain biotechnology providers” tied to foreign adversaries. The biotech companies of concern listed in the proposed legislation are WuXi AppTec, BGI, MGI and Complete Genomics. 

If signed into law, the legislation would prevent biopharma companies that contract with “companies of concern” from also having contracts with the U.S. government, according to the law firm Foley Hoag. 

Those smaller companies that had entered into manufacturing service agreements with the Chinese firms of concern, and now are claiming that they could be "materially Impacted" needed to make preemptive actions to mitigate any material impacts before entering such agreements. So my response to them is -- too bad -- so sad. 


https://www.biospace.com/article/companies-detail-potential-fallout-as-pressure-on-wuxi-apptec-builds/
<< Previous
Bullboard Posts
Next >>